{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:00Z","timestamp":1792788480726,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1192420N"],"award-info":[{"award-number":["1192420N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G055821N"],"award-info":[{"award-number":["G055821N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Belgian Foundation against Cancer","award":["C\/2020\/1374"],"award-info":[{"award-number":["C\/2020\/1374"]}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["Genomia \u2013 ERC-COG-2017-771945"],"award-info":[{"award-number":["Genomia \u2013 ERC-COG-2017-771945"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Variants in cardiomyopathy genes have been identified in patients with cancer therapy-related cardiac dysfunction (CTRCD), suggesting a genetic predisposition for the development of CTRCD. The diagnostic yield of genetic testing in a CTRCD population compared to a cardiomyopathy patient cohort is not yet known and information on which genes should be assessed in this population is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively included 46 cancer patients with a history of anthracycline induced CTRCD (defined as a decrease in left ventricular ejection fraction (LVEF) to\u2009&lt;\u200950% and a\u2009\u2265\u200910% reduction from baseline by echocardiography). Genetic testing was performed for 59 established cardiomyopathy genes. Only variants of uncertain significance and (likely) pathogenic variants were included. Diagnostic yield of genetic testing was compared with a matched cohort of patients with dilated cardiomyopathy (DCM,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946) and a matched cohort of patients without cardiac disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009111).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Average LVEF at time of CTRCD diagnosis was 30.1\u2009\u00b1\u200911.0%. Patients were 52.9\u2009\u00b1\u200914.6\u00a0years old at time of diagnosis and 30 (65.2%) were female. Most patients were treated for breast cancer or lymphoma, with a median doxorubicin equivalent dose of 300\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      [112.5-540.0]. A genetic variant, either pathogenic, likely pathogenic or of uncertain significance, was identified in 29\/46 (63.0%) of patients with CTRCD, which is similar to the DCM cohort (34\/46, 73.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.262), but significantly higher than in the negative control cohort (47\/111, 39.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018). Variants in\n                      <jats:italic>TTN<\/jats:italic>\n                      were the most prevalent in the CTRCD cohort (43% of all variants). All (likely) pathogenic variants identified in the CTRCD cohort were truncating variants in\n                      <jats:italic>TTN<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>There were no significant differences in severity of CTRCD and in recovery rate in variant-harbouring individuals versus non-variant harbouring individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this case-control study, cancer patients with anthracycline-induced CTRCD have an increased burden of genetic variants in cardiomyopathy genes, similar to a DCM cohort. If validated in larger prospective studies, integration of genetic data in risk prediction models for CTRCD may guide cancer treatment. Moreover, genetic results have important clinical impact, both for the patient in the setting of precision medicine, as for the family members that will receive genetic counselling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-024-00231-3","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T02:02:12Z","timestamp":1714442532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: a case control study"],"prefix":"10.1186","volume":"10","author":[{"given":"Hanne M.","family":"Boen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Alaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Goovaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan B.","family":"Saenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantijn","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vorlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Heidbuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lut","family":"Van Laer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Loeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline M.","family":"Van Craenenbroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"issue":"1","key":"231_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63\u201375.","journal-title":"Cardiovasc Drugs Ther"},{"key":"231_CR2","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur J. 2022;43(41):4229\u2013361."},{"issue":"9","key":"231_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","volume":"89","author":"J Herrmann","year":"2014","unstructured":"Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287\u2013306.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"231_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"231_CR5","doi-asserted-by":"publisher","first-page":"ytab333","DOI":"10.1093\/ehjcr\/ytab333","volume":"5","author":"S Moghadasi","year":"2021","unstructured":"Moghadasi S, Fijn R, Beeres S, Bikker H, Jongbloed JDH, Josephus Jitta D, et al. Case series, chemotherapy-induced cardiomyopathy: mind the family history! Eur Heart J Case Rep. 2021;5(10):ytab333.","journal-title":"Eur Heart J Case Rep."},{"issue":"6","key":"231_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cardfail.2017.03.003","volume":"23","author":"M Linschoten","year":"2017","unstructured":"Linschoten M, Teske AJ, Baas AF, Vink A, Dooijes D, Baars HF, Asselbergs FW. Truncating Titin (TTN) Variants in Chemotherapy-Induced Cardiomyopathy. J Cardiac Fail. 2017;23(6):476\u20139.","journal-title":"J Cardiac Fail"},{"issue":"12","key":"231_CR7","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/eurjhf\/hfq175","volume":"12","author":"MP van den Berg","year":"2010","unstructured":"van den Berg MP, van Spaendonck-Zwarts KY, van Veldhuisen DJ, Gietema JA, Postma A, van Tintelen JP. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? Eur J Heart Fail. 2010;12(12):1297\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"231_CR8","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1200\/JCO.2011.34.8052","volume":"29","author":"KE Shipman","year":"2011","unstructured":"Shipman KE, Arnold I. Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy. J Clin Oncol. 2011;29(18):e537\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"231_CR9","doi-asserted-by":"publisher","first-page":"e000116","DOI":"10.1136\/openhrt-2014-000116","volume":"1","author":"M Wasielewski","year":"2014","unstructured":"Wasielewski M, van Spaendonck-Zwarts KY, Westerink ND, Jongbloed JD, Postma A, Gietema JA, et al. Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart. 2014;1(1):e000116.","journal-title":"Open Heart"},{"issue":"1","key":"231_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","volume":"140","author":"P Garcia-Pavia","year":"2019","unstructured":"Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140(1):31\u201341.","journal-title":"Circulation"},{"issue":"4","key":"231_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12471-016-0812-z","volume":"24","author":"C Franssen","year":"2016","unstructured":"Franssen C, Gonz\u00e1lez MA. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J. 2016;24(4):259\u201367.","journal-title":"Neth Heart J"},{"issue":"3","key":"231_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/HCO.0000000000000512","volume":"33","author":"JE Wilcox","year":"2018","unstructured":"Wilcox JE, Hershberger RE. Genetic cardiomyopathies. Curr Opin Cardiol. 2018;33(3):354\u201362.","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"231_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa1110186","volume":"366","author":"DS Herman","year":"2012","unstructured":"Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"231_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur J Heart Fail. 2017;19(1):9\u201342.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"231_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2007","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2007;29(2):270\u20136.","journal-title":"Eur Heart J"},{"issue":"5402","key":"231_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","volume":"2","author":"PP Rickham","year":"1964","unstructured":"Rickham PP. Human experimentation.Ccode of ethics of the world medical association. Declaration of Helsinki. Br Med J. 1964;2(5402):177.","journal-title":"Br Med J"},{"issue":"3","key":"231_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jmoldx.2017.01.010","volume":"19","author":"D Proost","year":"2017","unstructured":"Proost D, Saenen J, Vandeweyer G, Rotthier A, Alaerts M, Van Craenenbroeck EM, et al. Targeted next-generation sequencing of 51 genes involved in primary electrical disease. J Mol Diagn. 2017;19(3):445\u201359.","journal-title":"J Mol Diagn"},{"key":"231_CR18","doi-asserted-by":"crossref","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","DOI":"10.1038\/gim.2015.30"},{"issue":"7","key":"231_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41431-019-0364-y","volume":"27","author":"I Luyckx","year":"2019","unstructured":"Luyckx I, Kumar AA, Reyniers E, Dekeyser E, Vanderstraeten K, Vandeweyer G, et al. Copy number variation analysis in bicuspid aortic valve-related aortopathy identifies TBX20 as a contributing gene. Eur J Hum Genet. 2019;27(7):1033\u201343.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"231_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher M, Witten DM, Jain P, O\u2019Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310\u20135.","journal-title":"Nat Genet"},{"issue":"D1","key":"231_CR21","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gky1016","volume":"47","author":"P Rentzsch","year":"2019","unstructured":"Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"231_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.053033","volume":"144","author":"E Jordan","year":"2021","unstructured":"Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation. 2021;144(1):7\u201319.","journal-title":"Circulation"},{"key":"231_CR23","doi-asserted-by":"crossref","unstructured":"Boen HM, Loeys BL, Alaerts M, Saenen JB, Goovaerts I, Van Laer L, et al. Diagnostic yield of genetic testing in heart transplant recipients with prior cardiomyopathy. J Heart Lung Transplant. 2022;41(9):1218-27.","DOI":"10.1016\/j.healun.2022.03.020"},{"key":"231_CR24","doi-asserted-by":"crossref","unstructured":"Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguch\u00eda J, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018;71(20):2293\u2013302.","DOI":"10.1016\/j.jacc.2018.03.462"},{"key":"231_CR25","doi-asserted-by":"crossref","unstructured":"van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D, Bollen IAE, Sliwa K, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Euro Heart J. 2014;35(32):2165\u201373.","DOI":"10.1093\/eurheartj\/ehu050"},{"issue":"10406","key":"231_CR26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","volume":"402","author":"S Heymans","year":"2023","unstructured":"Heymans S, Lakdawala NK, Tsch\u00f6pe C, Klingel K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet. 2023;402(10406):998\u20131011.","journal-title":"Lancet"},{"issue":"2","key":"231_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","volume":"53","author":"AR Harper","year":"2021","unstructured":"Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021;53(2):135\u201342.","journal-title":"Nat Genet"},{"issue":"4","key":"231_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","volume":"2","author":"S Bhatia","year":"2020","unstructured":"Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC CardioOncol. 2020;2(4):539\u201352.","journal-title":"JACC CardioOncol"},{"key":"231_CR29","doi-asserted-by":"publisher","first-page":"5818612","DOI":"10.1155\/2022\/5818612","volume":"2022","author":"Y Ding","year":"2022","unstructured":"Ding Y, Du K, Niu Y-J, Wang Y, Xu X. Genetic susceptibility and mechanisms underlying the pathogenesis of anthracycline-associated cardiotoxicity. Oxid Med Cell Longev. 2022;2022:5818612.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"231_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/FPC.0000000000000284","volume":"27","author":"QS Wells","year":"2017","unstructured":"Wells QS, Veatch OJ, Fessel JP, Joon AY, Levinson RT, Mosley JD, et al. Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenet Genomics. 2017;27(7):247\u201354.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"231_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/bjh.12516","volume":"163","author":"SH Armenian","year":"2013","unstructured":"Armenian SH, Ding Y, Mills G, Sun C, Venkataraman K, Wong FL, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol. 2013;163(2):205\u201313.","journal-title":"Br J Haematol"},{"issue":"5","key":"231_CR32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaccao.2020.11.004","volume":"2","author":"MA Chaix","year":"2020","unstructured":"Chaix MA, Parmar N, Kinnear C, Lafreniere-Roula M, Akinrinade O, Yao R, et al. Machine learning identifies clinical and genetic factors associated with anthracycline cardiotoxicity in pediatric cancer survivors. JACC CardioOncol. 2020;2(5):690\u2013706.","journal-title":"JACC CardioOncol"},{"issue":"13","key":"231_CR33","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","volume":"30","author":"H Visscher","year":"2012","unstructured":"Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dub\u00e9 MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422\u20138.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"231_CR34","doi-asserted-by":"publisher","first-page":"10015","DOI":"10.1200\/JCO.2019.37.15_suppl.10015","volume":"37","author":"X Wang","year":"2019","unstructured":"Wang X, Chen Y, Hageman L, Singh P, Landier W, Blanco JG, et al. Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): a COG-ALTE03N1 and CCSS report. J Clin Oncol. 2019;37(15_suppl):10015.","journal-title":"J Clin Oncol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-024-00231-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T02:14:29Z","timestamp":1714443269000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-024-00231-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["231"],"URL":"https:\/\/doi.org\/10.1186\/s40959-024-00231-3","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the local Ethics Committee of the University Hospital Antwerp (reference number:20\/02\/009). Written informed Consent was obtained from all included patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}